Overview

Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to understand the gastrointestinal transit time and disintegration behavior of the formulations in vivo in normal healthy volunteers when ALLN-346 formulations are given with light meal or in fasted or other fed states.
Phase:
Phase 1
Details
Lead Sponsor:
Allena Pharmaceuticals
Collaborator:
BDD Pharma Ltd
Treatments:
Rasburicase
Uric Acid